Roche (ROG) Pharma Day 2026 summary

Strategic Progress and Portfolio Evolution

• Achieved strong sales growth and double-digit margin expansion, with HY 2026 sales up 6% and core operating profit up 10% compared to the previous year.

• Refined the pipeline by removing lower-value programs, focusing on high-value assets, and targeting up to 20 new molecular entities for launch by 2030.

• Discontinued development of amugabart in obesity due to insufficient efficacy, while adding promising assets like TANPELI and VEGF IL-6 DudaFab.

• No patent cliff expected before 2030, with multiple new launches planned through 2027 and sustained growth projected beyond 2030.

• Major late-stage readouts expected from 2027 to 2030 in IBD, Alzheimer's, MASH, Parkinson's, obesity, and hypertension.

R&D Excellence, Portfolio Transformation, and AI Integration

• Fully implemented the BAR framework, increasing portfolio value by up to 93% since 2023 and shifting to higher-value, lower-risk assets.

• Achieved over 80% Phase III success rate in 2026 YTD, with 47 assets added since 2024 through early R&D and partnerships.

• R&D cycle times reduced by ~19 months, with CHF 1.6–2 billion reallocated to support the pharma portfolio and transformative programs.

• AI and digitalization embedded across R&D, manufacturing, and commercialization, impacting 40% of portfolio decisions and enabling rapid iteration and efficiency gains.

• Built proprietary AI models, digital twins for manufacturing, and autonomous labs, with Lab-in-the-Loop and digital twin platforms enhancing productivity.

Therapeutic Area Focus and Pipeline Highlights

• Five core therapeutic areas (Oncology/Hematology, Neurology, Immunology, Ophthalmology, CVRM) cover 60% of global disease burden.

• Oncology/Hematology: Positive Phase III results for giredestrant, divarasib, SkyGlow, and Lunsumio; advancing best-in-class assets and novel modalities.

• Neurology: Fenebrutinib filed in RMS/PPMS, trontinemab in Phase III for Alzheimer's, prasinezumab in Phase III for Parkinson's, with data expected in 2028.

• Immunology: Gazyva filed for SLE and MN, cefaxterson/sefaxersen positive in IgA nephropathy, afimkibart Phase III in IBD, and p40xTL1A bispecific in Phase II for UC.

• Ophthalmology: Verbismo/Vabysmo leads in retina, VEGF IL-6 bispecific advancing to Phase III, vamikibart filed in UME, Susvimo approved in EU for nAMD.

• CVRM: Enesipatide demonstrated >22% weight loss and 2.65% HbA1c reduction in Phase II; oral GLP-1, amylin, petrelintide, zilebesiran, and pegozafermin advancing in obesity, T2D, hypertension, and MASH.